| Dr Julie M Olivencia Sanabria, MD | |
|
#55 Calle Del Carmen, Fajardo, PR 00738 | |
| (787) 860-3558 | |
| (787) 860-3330 |
| Full Name | Dr Julie M Olivencia Sanabria |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | #55 Calle Del Carmen, Fajardo, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053355784 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0804X | Psychiatry & Neurology - Child & Adolescent Psychiatry | 9364 (Puerto Rico) | Primary |
| Entity Name | N.o.r. Community Mental Health, Corp. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659337699 PECOS PAC ID: 2466416482 Enrollment ID: O20041118000473 |
News Archive
In the hours and days following a spinal cord injury, the gears that control the body's internal clocks fall profoundly out of sync, impacting body temperature, hormone fluctuation, immunity and the timing of a host of other bodily processes, according to new University of Colorado Boulder research.
Work hour restrictions for resident physicians, revised nationally four years ago largely to protect patients against physician trainees' fatigue-related errors, have not had the desired effect of lowering postoperative complication rates in several common surgical specialties, according to new study results.
The U.S. Food and Drug Administration today approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B.
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced dosing of the first patients enrolled in the Company's Phase 2b study of PG324, a novel, fixed-combination of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.
The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.
› Verified 6 days ago
| Entity Name | A.p. Community Mental Services, Corp. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306175500 PECOS PAC ID: 0648469213 Enrollment ID: O20110408000204 |
News Archive
In the hours and days following a spinal cord injury, the gears that control the body's internal clocks fall profoundly out of sync, impacting body temperature, hormone fluctuation, immunity and the timing of a host of other bodily processes, according to new University of Colorado Boulder research.
Work hour restrictions for resident physicians, revised nationally four years ago largely to protect patients against physician trainees' fatigue-related errors, have not had the desired effect of lowering postoperative complication rates in several common surgical specialties, according to new study results.
The U.S. Food and Drug Administration today approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B.
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced dosing of the first patients enrolled in the Company's Phase 2b study of PG324, a novel, fixed-combination of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.
The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Julie M Olivencia Sanabria, MD Po Box 1522, Las Piedras, PR 00771-1522 Ph: (787) 860-3558 | Dr Julie M Olivencia Sanabria, MD #55 Calle Del Carmen, Fajardo, PR 00738 Ph: (787) 860-3558 |
News Archive
In the hours and days following a spinal cord injury, the gears that control the body's internal clocks fall profoundly out of sync, impacting body temperature, hormone fluctuation, immunity and the timing of a host of other bodily processes, according to new University of Colorado Boulder research.
Work hour restrictions for resident physicians, revised nationally four years ago largely to protect patients against physician trainees' fatigue-related errors, have not had the desired effect of lowering postoperative complication rates in several common surgical specialties, according to new study results.
The U.S. Food and Drug Administration today approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B.
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced dosing of the first patients enrolled in the Company's Phase 2b study of PG324, a novel, fixed-combination of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.
The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.
› Verified 6 days ago
Dr. Ivette Franceschi Nazario, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 410 Ave General Valero, Torre Medica Del Este - Suite 405, Fajardo, PR 00738 Phone: 787-860-0768 Fax: 787-801-0587 | |
Dr. Gerardo Tejedor Gonzalez, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: #55 Calle Del Carmen, Fajardo, PR 00738 Phone: 787-860-3558 Fax: 787-860-3330 | |
Dr. Jaime Marchena Arraut, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 410 Ave General Valero, Torre Medica Del Este - Suite 405, Fajardo, PR 00738 Phone: 787-860-0768 Fax: 787-801-0587 | |
Dr. Maria M. Wiscovitch, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: Carretera 194 Cc21 Fajardo Gardens, Fajardo, PR 00738 Phone: 787-655-7002 Fax: 787-655-7004 | |
Dr. Grace Palmer Quinones, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: #55 Calle Del Carmen, Fajardo, PR 00738 Phone: 787-860-3558 Fax: 787-860-3330 | |
Luce Villafane Carmona, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: Union 46 A, Fajardo, PR 00738 Phone: 787-863-2205 Fax: 787-860-2585 |